Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Update on Interim Dividend Timetable

9 Nov 2021 16:36

RNS Number : 8493R
Alliance Pharma PLC
09 November 2021
 

For immediate release

9 November 2021

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Update on interim dividend timetable

 

In the Group's interim results for the six months ended 30 June 2021 announced on 21 September 2021, Alliance stated that its 2021 interim dividend payment of 0.563p per share (the "Interim Dividend") would be paid on 7 January 2022 to shareholders on the register on 24 December 2021.

 

Alliance would now like to update the market that it has brought forward the record date for the Interim Dividend to 17 December 2021, with the payment date remaining as 7 January 2022 as previously announced.

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams

 

Corporate Broking: Patrick Robb

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVBLBDBSXGDGBC
Date   Source Headline
21st Aug 20158:45 amRNSExercise of Share Options
17th Aug 20157:00 amRNSNotification of Interim Results
13th Jul 20157:00 amRNSPre-Close Trading Update
10th Jul 20157:00 amRNSAppointment of Finance Director
23rd Jun 20151:30 pmRNSDirector Shareholding
17th Jun 20155:30 pmRNSDirector Shareholding
1st Jun 20153:30 pmRNSExercise of Share Options
27th May 20152:00 pmRNSShare Options
27th May 20157:00 amRNSAGM Statement
20th Apr 20157:00 amRNSHardman & Co issues research report
15th Apr 20157:00 amRNSExercise of Share Options
10th Apr 20157:00 amRNSAnnual Report and AGM Notice
25th Mar 20157:00 amRNSPreliminary Results
3rd Mar 20159:30 amRNSExercise of Share Options
17th Feb 20157:00 amRNSDirectorate Change
16th Feb 20157:00 amRNSNotification of Preliminary Results
2nd Feb 201512:15 pmRNSAcquisition of MacuVision
26th Jan 20157:00 amRNSAppointment of Non-Executive Director
19th Jan 20157:00 amRNSPre-Close Trading Update
18th Dec 20143:27 pmRNSDirectorate Change
10th Sep 20147:00 amRNSAlliance Pharma PLC Interim Results
5th Aug 20147:00 amRNSNotification of Interim Results
9th Jul 20147:00 amRNSPre-Close Trading Update
19th Jun 20145:35 pmRNSExercise of Share Options
21st May 20147:00 amRNSAGM Statement
11th Apr 20142:30 pmRNSShare Options
11th Apr 20147:00 amRNSMajor Interest in Shares
10th Apr 20142:57 pmRNSExercise of Share Options
10th Apr 20147:00 amRNSAnnual Report and Notice of AGM
7th Apr 20142:45 pmRNSTR-1: Notification of Major Interest in Shares
1st Apr 20147:00 amRNSAppointment of Non-Executive Director
26th Mar 20147:00 amRNSPreliminary Results
4th Feb 20147:00 amRNSNotification of Preliminary Results
23rd Jan 20149:30 amRNSTR-1: Notification of Major Interest in Shares
20th Jan 20147:00 amRNSDirector Shareholding
14th Jan 20147:00 amRNSAcquisition in Germany
14th Jan 20147:00 amRNSPre-Close Trading Update
30th Dec 20132:00 pmRNSDirectorate Change
19th Dec 20132:45 pmRNSCULS Conversion and Additional Listing
18th Dec 20137:00 amRNSAcquisition of Lypsyl
9th Dec 20137:00 amRNSMajor Interest in Shares
2nd Dec 20136:00 pmRNSCULS Conversion and Additional Listing
11th Nov 20134:20 pmRNSCULS Conversion and Additional Listing
7th Nov 20131:46 pmRNSCompulsory Conversion of CULS
28th Oct 20133:01 pmRNSCULS Conversion and Additional Listing
25th Oct 20138:00 amRNSMajor Interest in Shares
24th Oct 20135:55 pmRNSShare Options
22nd Oct 20139:30 amRNSCULS Conversion and Additional Listing
11th Oct 20137:00 amRNS£55 Million Bank Facilities
16th Sep 20132:01 pmRNSCULS Conversion and Additional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.